2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer

Front

1 of 3 · Front

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer

In one breath

The 2022 PSOGI consensus on HIPEC for colorectal peritoneal metastases: after complete cytoreductive surgery, HIPEC is conditionally recommended despite the negative PRODIGE-7 results — with short-duration high-dose oxaliplatin strongly rejected and mitomycin-C weakly favoured.

Edition2022 Consensus

Issued byPeritoneal Surface Oncology Group International (PSOGI)

Place of issueInternational

PublishedAnnals of Surgical Oncology · 2024;31(1):567–576

⏳ Pending verification

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 1

2 of 3 · Back 1

Back colours mark the reading sections — the chapter colour is the band and chip.

§1 · What it covers

This guideline covers selected adults with colorectal peritoneal metastases undergoing CRS, including primary and selected recurrent disease.

Applies to: Selected adults with colorectal peritoneal metastases undergoing CRS, including primary and selected recurrent disease.

§2 · Key recommendations

CRS can provide potentially curative outcomes in selected patients.
After complete CRS, PSOGI conditionally recommends HIPEC despite negative PRODIGE-7 results.
the panel strongly rejected short-duration/high-dose oxaliplatin HIPEC and weakly favoured mitomycin-C, especially the Dutch protocol (35 mg/m², 90 minutes, three fractions).
More than 90% supported HIPEC after primary and after secondary CRS when recurrence was >1 year after index surgery.

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 2

3 of 3 · Back 2

Back colours mark the reading sections — the chapter colour is the band and chip.

§3 · Evidence & grading

GRADE/PICO evidence review; evidence was weak or very weak for 9/10 clinical questions. Delphi: 70/90 eligible panelists completed both rounds; consensus threshold ≥50% for four-point grading or ≥70% for combined categories.

§4 · What changed in this edition

Not yet established — pending verification.

§5 · Source & working link

Hübner M, et al. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer. Ann Surg Oncol. 2024;31(1):567–576. doi:10.1245/s10434-023-14368-5 · PMID 37940803.

Publisher — the record's original_url, carried verbatim ↗DOI — 10.1245/s10434-023-14368-5 ↗PubMed — PMID 37940803 ↗

Link check 2026-11-11: the publisher (PMC) URL, DOI and PubMed record (PMID 37940803) all fetched live — title, journal, volume and pages match the record.

Source: Tamer-supplied guideline index, intake 2026-11-10 (record #123, Domain 11) · Card built 2026-11-11 (Wave D) from the record itself; the §5.2 verification pass (UpToDate + Medscape → Perplexity → Tamer decision) has not yet run on this card. ⚑ Conflict flag on the source record — documented cross-society disagreement (intake DOCX Table 2): Colorectal peritoneal metastases — PSOGI HIPEC consensus 2022 vs ESMO/North American guidance in the post-PRODIGE-7 era. Unresolved — pending the verification pass (UpToDate + Medscape → Perplexity → Tamer decision).

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

gl-div01-psogi-hipec-colorectal-2022GS.code · Guidelines

More in Division 1 · Colorectal, Anorectal & Pilonidal Disease

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

EAES-SAGES Clinical Practice Guideline Update: Multi-Society Recommendations on Key Controversies in the Management of Diverticular Disease

A multi-society update on the key controversies in diverticular disease: no routine antibiotics for uncomplicated diverticulitis, elective resection for persistent symptoms after recurrent episodes or recovery from a first abscess, and no routine follow-up colonoscopy after a first uncomplicated episode.

2026 Update · European Association for Endoscopic Surgery (EAES) and SAGES, with AAST, CSSANZ, EAST, ESCP, UEG and WSES participation

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases

The INDEPSO-ISPSM consensus on colorectal peritoneal metastases, written for Indian epidemiology and access: cytoreductive surgery for selected isolated or resectable disease, adjuvant systemic chemotherapy after CRS, and HIPEC outside trials only selectively — particularly at PCI 11–15.

2024 · Indian Network for Development of Peritoneal Surface Oncology (INDEPSO) and Indian Society of Peritoneal Surface Malignancies (ISPSM)

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

Multi-Society Guideline on Cytoreductive Surgery and HIPEC: Methodology and Overview of the Results

The multi-society CRS/HIPEC guideline's methodology and overview paper: seven recommendations built by GRADE ADOLOPMENT — conditional for metachronous colorectal and gastric peritoneal metastases, strong for pseudomyxoma, peritoneal mesothelioma and advanced ovarian cancer after neoadjuvant chemotherapy.

2024 · PSOGI with the European Society of Surgical Oncology, ERN-EURACAN, the Society of Surgical Oncology and partner societies (14 countries)